No VC Firms Called Themselves Life Sciences Funds in the Late 1980s
Peter Parker · 20VC: Why Process is Everything In Good Venture Firms, Why GPs Should Have More Empathy For LPs and Lessons from 32 Years In VC, Chairing Over 25 Boards with Peter Parker, Managing Partner @ Bioinnovation Capital · Jun 11, 2018 · at 5:35
Peter Parker, Managing Partner at BioInnovation Capital, discusses how specialization evolved in the venture capital industry over his 30-plus year career.
0:00 / 0:07exact quote · 7.9s
720p mp4 · rendered on demand · StarZero watermark
“So back in the late eighties, there were very few specialized firms at all. None that I knew of that would call themselves, for instance, life sciences firms.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Peter Parker
No New Major Pharma Companies Will Be Built From Biotech VC
“There are very few, there won't be any new major pharmaceutical companies created out of biotech VC money anymore. Really all about creating companies that can exit to these people.”
BioInnovation Capital Targets Gains on Two-Thirds of Portfolio Companies
“I'd like to see a portfolio with two thirds of my companies being gains for us. And so not relying on the 50 to one winner to Drive the whole portfolio. I think that's just too hard to do.”
BioInnovation Capital Requires Unanimous Partner Consensus to Invest
“We passed on deals where one partner had just serious reservations and four would have voted for it. And that was true at Ampersand. It's true at Bioinnovation Capital as well.”
VCs Are Middlemen and the Cult of Personality Is Unwarranted
“My view of the world is we're middlemen. It's their capital, and we're finding great places to put it. That sounds pretty pedestrian. I really don't like the cult of Personality that sometimes accrues to very, very big names in the venture business. I'm not su…”